News Posts List

ASPEN, a new investigator-initiated study being led by Duke University, is now enrolling patients with metastatic renal-cell carcinoma with non-clear cell histology.  Click here for more information.

Listen to the podcast featuring lead investigator Andrew J. Armstrong, MD ScM, Assistant Professor of Medicine and Surgery at Duke Comprehensive Cancer Center, as he describes this trial. 

Patients interested should refer to clinicaltrials.gov for the nearest open site.